Are private-labeled biosimilars from PBM distributors a lifeline for the biosimilar industry or another barrier to ensuring biosimilar competition into the future? In 2023, adalimumab biosimilars gained virtually no traction when covered at parity with the reference product Humira®. Only once CVS Health launched its Cordavis distributor subsidiary in April 2024 did adalimumab biosimilar uptake … Continue reading PBM Private Labeling: A Boon or Bane to Biosimilar Drug Makers?